Last reviewed · How we verify
glucocorticoid and immunosuppressant
At a glance
| Generic name | glucocorticoid and immunosuppressant |
|---|---|
| Sponsor | Qilu Hospital of Shandong University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus (PHASE3)
- A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) (PHASE2)
- A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (PHASE3)
- Myositis Interstitial Lung Disease Nintedanib Trial (PHASE4)
- PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis
- AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |